RayKnowChina Research Map
Shortlist0

Not yet recruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Guangxi Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06680115, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;

    Inclusion criterion 1

  3. Staging TanyN3M0 (AJCC/UICC 9th edition) ;

    Inclusion criterion 3

  4. Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;

    Exclusion criterion 5

  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;

    Inclusion criterion 4

  6. White blood cell≥3.5×10\^9/L,Neutrophils≥1.5×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L ;

    Inclusion criterion 5

    Transaminases≤2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal;

    Inclusion criterion 6

    Creatinine clearance ≥60 ml/min;

    Inclusion criterion 7

  7. HBsAg positive and HBV DNA >1×103 copy/ml;

    Exclusion criterion 1

    Patients with positive HCV antibody test results;

    Exclusion criterion 2

    Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;

    Exclusion criterion 8

    Human immunodeficiency virus (HIV) infection;

    Exclusion criterion 10

  8. Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06680115, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;
  • Age≥18 years;
  • Staging TanyN3M0 (AJCC/UICC 9th edition) ;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  • White blood cell≥3.5×10\^9/L,Neutrophils≥1.5×10\^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10\^9/ L ;
  • Transaminases≤2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal;
  • Creatinine clearance ≥60 ml/min;
  • Signed informed consent form.

Exclusion Criteria:

  • HBsAg positive and HBV DNA >1×103 copy/ml;
  • Patients with positive HCV antibody test results;
  • Active, known, or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions that do not require systemic treatment, such as vitiligo, psoriasis, or hair loss, may be enrolled;
  • History of interstitial lung disease;
  • Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;
  • Have received or will receive live vaccine within 30 days before signing the informed consent;
  • Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);
  • Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;
  • The subject is known to have a prior allergy to macromolecular protein preparations, or any of the components of sindillizumab;
  • Human immunodeficiency virus (HIV) infection;
  • Other conditions, as determined by the investigator, that may affect subjects' safety or compliance with the study include symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infection requiring systemic treatment, mental illness, or family and social factors.

Quoted from ClinicalTrials.gov, NCT06680115, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06680115, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06680115